Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Delivering High-Quality Care Under Value-Based Payment Models: Where Are We Now?
September 15th 2018

Delivering High-Quality Care Under Value-Based Payment Models: Where Are We Now?

Jaime Rosenberg
As the term “value” has become a norm in healthcare, specifically in oncology, panelists at a National Comprehensive Cancer Network policy summit offered perspectives on where we are now in delivering high-quality cancer care under value-based payment models.
Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News
September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use
September 14th 2018

NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use

Samantha DiGrande
A recent report from the National Comprehensive Cancer Network (NCCN) investigated the current state of chimeric antigen receptor (CAR) T-cell therapy and future strategies to consider as the novel immunotherapy evolves and is used in the treatment of more patients.
This Week in Managed Care: September 14, 2018
September 14th 2018

This Week in Managed Care: September 14, 2018

This week, the top managed care news included medical groups asking CMS to halt or slow down its plans to cut physician reimbursement for evaluation and management services; the Senate weighs a package of bills to combat the opioid epidemic; new research shows the Affordable Care Act pushed the uninsured rate down to 10%.
Dr Don Dizon Highlights Services Insurance Should Cover for Women Who Had Breast Cancer
September 14th 2018

Dr Don Dizon Highlights Services Insurance Should Cover for Women Who Had Breast Cancer

There are medications, procedures, and techniques that insurers could do a better job covering that would improve quality for women after breast cancer, said Don S. Dizon, MD, FACP, FASCO, director of Women's Cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and associate professor of medicine at The Warren Alpert Medical School of Brown University.
Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells
September 13th 2018

Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells

Laura Joszt, MA
Researchers at Baylor College of Medicine have found that preventing a mutated protein from leaving the nucleus and traveling to the cytoplasm of the cell can help inhibit the growth of leukemic cells in acute myeloid leukemia.
Cautious Optimism: OCM Participants Seem to Have Improved in Performance Period 2
September 13th 2018

Cautious Optimism: OCM Participants Seem to Have Improved in Performance Period 2

Laura Joszt, MA
An early review of the second performance period of the Oncology Care Model (OCM) seems to show improvements over the first period.
Site Logo
September 13th 2018

Study Discerns Rare Risks of Fatal Side Effects From Cancer Immunotherapy

Allison Inserro
Researchers determined the incidence and timing of rare, fatal side effects from immune checkpoint inhibitors, and said the number is still extremely low.
EU Approves Keytruda for First-Line Treatment of Metastatic Nonsquamous NSCLC
September 12th 2018

EU Approves Keytruda for First-Line Treatment of Metastatic Nonsquamous NSCLC

Samantha DiGrande
Pembrolizumab (Keytruda) earned European approval this week, in combination with platinum-based pemetrexed, for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults whose tumors lack EGFR or ALK mutations.
Site Logo
September 11th 2018

OneOncology Launches to Enable Better Cancer Care in Communities Across America

Three leading oncology practices unite with partners in technology and finance to announce the launch of OneOncology, a patient-centric, physician-driven, and technology-powered company with a mission to improve the lives of everyone living with cancer.
Prescription Drug Coverage Improved Survival for Patients With MM
September 9th 2018

Prescription Drug Coverage Improved Survival for Patients With MM

Laura Joszt, MA
Patients with multiple myeloma (MM) who are enrolled in a Medicare Part D plan or other creditable prescription drug coverage have better survival than patients without prescription drug coverage. According to a study in Journal of Clinical Oncology, this improved survival seemed to be a result of patients having access to all treatment options.
HIV/AIDS Research Has Positive Impacts Across Other Medical Fields
September 6th 2018

HIV/AIDS Research Has Positive Impacts Across Other Medical Fields

Jaime Rosenberg
In addition to the advances made in the HIV space, such as antiretroviral therapies and pre-exposure prophylaxis, the years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.
Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care
September 5th 2018

Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care

As the oncology landscape continues to rapidly evolve, access to real-time data has become increaisngly important, and technology-based medical startups have made their way to the front of the lines with point-of-care tools that use technology to transform cancer care.
Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma
September 4th 2018

Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma

Laura Joszt, MA
Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models
September 2nd 2018

Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models

Laura Joszt, MA
As the healthcare system considers alternative payment models that reward high-value care delivery, programs that utilize lay health workers (LHW) may be valuable. A study in JAMA Oncology analyzed whether an LHW program can increase the documentation of patients’ care preferences.
What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller
August 31st 2018

What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller

AJMC Staff
A judge tossed a lawsuit brought by pharmaceutical companies to block a California law requiring advance notice of big price increases; the FDA is testing all angiotensin II receptor blockers (ARBs) over a discovered impurity that is linked to cancer; research in monkeys has suggested that an experimental painkiller is effective at easing pain without being addictive.
Dr Don Dizon: Discussing Sexual Health Needs With Patients With Cancer
August 31st 2018

Dr Don Dizon: Discussing Sexual Health Needs With Patients With Cancer

Most oncologists aren’t comfortable discussing sexual health needs with their patients, but there are places where sexual health services for patients with cancer are starting to gain foothold, said Don S. Dizon, MD, FACP, FASCO, director of Women's Cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and associate professor of medicine at The Warren Alpert Medical School of Brown University.
Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers
August 31st 2018

Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers

Laura Joszt, MA
A survey of patients in the United Kingdom who were diagnosed with cancer found that patients with blood cancers were the least likely to say they completely understood what was wrong when the doctor explained it. They were also less likely to say that their treatment options were explained before treatment started compared with patients with other cancers.
Site Logo
August 30th 2018

Medicaid Expansion Helped Reduce Disparities Among Different Groups With Cancer

Allison Inserro
The expansion of Medicaid may mitigate health disparities in cancer diagnosis, according to a recent study that found state variation in reductions in the percentage of uninsured patients aged 18 to 64 years diagnosed with cancer. The researchers said that the results have implications for future disparities in state mortality rates, because health insurance coverage is linked to the ability to have better treatment and survival after diagnosis.
Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population
August 28th 2018

Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population

Laura Joszt, MA
As cure rates for young patients with Hodgkin lymphoma (HL) improve, the historically negative impact of treatments has to be considered. However, a new study has found that over time, childbearing rates for female survivors of HL have improved to the point of approaching the rates of the general population.
Podcast: This Week in Managed Care—Patient-Reported Outcomes With CAR T and Other Health News
August 25th 2018

Podcast: This Week in Managed Care—Patient-Reported Outcomes With CAR T and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Utilizing Bioinformatics to Determine a Patient's Response to Immunotherapy
August 24th 2018

Utilizing Bioinformatics to Determine a Patient's Response to Immunotherapy

Samantha DiGrande
A recent study at Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy discovered a new way to use bioinformatics to determine how a patient’s immune system responds to immunotherapy.
This Week in Managed Care: August 24, 2018
August 24th 2018

This Week in Managed Care: August 24, 2018

This week, the top managed care news included a panel mostly endorsed the use of patient-reported outcomes for coverage of chimeric antigen receptor T-cell therapy; the US Preventive Services Task Force released new recommendations for cervical cancer screening; research found accountable care organization penetration may be changing how physicians work.
NCCN Releases New Guidelines for Rare Cancers During Pregnancy
August 23rd 2018

NCCN Releases New Guidelines for Rare Cancers During Pregnancy

Samantha DiGrande
Earlier this month, the National Comprehensive Cancer Network (NCCN) released new treatment guidelines for a group of rare cancers that impact women during pregnancy.
Site Logo
August 23rd 2018

CURE Media Group Expands Strategic Alliance Partnership Program With The Biden Cancer Initiative

Sister publication American Journal of Managed Care® will also be a part of this collaboration.
Tracking ctDNA Levels Can Quickly Predict Response to Lymphoma Therapy
August 22nd 2018

Tracking ctDNA Levels Can Quickly Predict Response to Lymphoma Therapy

Laura Joszt, MA
A blood test that tracks the rise and fall of circulating tumor DNA (ctDNA) levels can predict how patients with diffuse large B-cell lymphoma will respond to therapy within days of starting treatment.
Dr Denalee O'Malley Discusses Unique Concerns of Younger Patients With Breast Cancer
August 22nd 2018

Dr Denalee O'Malley Discusses Unique Concerns of Younger Patients With Breast Cancer

Younger, premenopausal patients with breast cancer can have unique issues that providers need to keep in mind, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.
Site Logo
August 22nd 2018

From the Editor-in-Chief: What Happens Next?

Joseph Alvarnas, MD
A letter from our Editor-in-Chief, Joseph Alvarnas, MD.
Site Logo
August 22nd 2018

Survivorship Care Throughout the Cancer Journey

Don Champlain, MHA, RN Lucio Gordan, MD
Leaders at Florida Cancer Specialists discuss the cancer survivorship program they've created to meet the needs of their diverse population of patients.
Site Logo
August 22nd 2018

Conference Coverage: NCCN Policy Summit 2018

Mary Caffrey
<1
...
394041424344454647
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo